Good morning :)
$
₹
E

Estrella Immunopharma Inc.

ESLAW

NASDAQ
E

Estrella Immunopharma Inc.

ESLAW

NASDAQ
$0.070% (-)
$
₹
$0.070% (-)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Unknown

Recent listing (market-cap unavailable as on date)

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

—
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Company Profile

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Peers

Peers

Hmm, looks like data is currently unavailable. Once it's updated, you can view it here

Financials

Financials

Income

Balance Sheet

Cash Flow

-4.8
-0.6
-2.2
-2.3
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue000-000000
Net Income-0.46-3.95-3.37-1.05-2.10-5.54-4.80-0.61-2.29-2.30
Net Profit Margin----------
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Estrella Immunopharma Inc. (ESLAW) share price today is $0.07 as of September 15, 2026 at 9:32 PM IST. The stock touched a day high of $0.00 and a day low of $0.00.

  2. Estrella Immunopharma Inc. stock trades on NASDAQ under the ticker symbol ESLAW.

  3. Estrella Immunopharma Inc.'s market capitalization is N/A as of September 15, 2026 at 9:32 PM IST.

  4. Estrella Immunopharma Inc.'s price-to-earnings (P/E) ratio is N/A as of September 16, 2026.

  5. Estrella Immunopharma Inc.'s price-to-book (P/B) ratio is 0 as of September 16, 2026.

  6. Yes, You can buy Estrella Immunopharma Inc. shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Estrella Immunopharma Inc. shares in three steps: 1. Search Estrella Immunopharma Inc. on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Estrella Immunopharma Inc. trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Estrella Immunopharma Inc. (ESLAW) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 142.8571 shares at the current price of $0.07.

Loading...